Basic Principles of Immunotherapy for Neurologic Diseases

ABSTRACT

Immunosuppressive drugs and immunomodulating procedures can improve the quality of life in patients with immune-related neurologic diseases and can even be lifesaving if properly used to avoid deleterious or irreversible adverse effects. For the successful use of these drugs or procedures, the treating physician must be familiar and comfortable with the drugs' mode of action, the accuracy of the diagnosis, the goals and expectations of therapy, and the risk-benefit ratio of the therapy. Improvement must be based on a beneficial change in activities of daily living and not solely on a change in the laboratory test values.

KEYWORDS

Immunomodulation - neuroimmunological diseases - immunosuppressive therapy

REFERENCES

• 1 Moalem G, Gdalyahu A, Shani Y. et al . Production of neurotrophins by activated T cells: implications for neurotrophic autoimmunity.  J Autoimmun . 2000;  15 331-345
• 2 Hohlfeld R, Kerschensteiner M, Stadelmann C, Lassmann H, Wekerle H. The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis.  J Neuroimmunol . 2000;  107 161-166
• 3 Kerschensteiner M, Gallmeier E, Behrens L. et al . Activated human T cells, B cells and monocytes produce brain-derived neurotrophic factor (BDNF) in vitro and in brain lesions: a neuroprotective role of inflammation?.  J Exp Med . 1999;  189 865-870
• 4 Dalakas M C. Neuroimmunotherapy: a practical approach to the treatment of immune-mediated neurologic diseases.  Sem Neurol . 1994;  14 97-105
• 5 Dalakas M C. Immunotherapies in the treatment of neuromuscular diseases. In: Katirji B, Kaminski HJ, Preston DC, Ruff RL, Shapiro BE, eds. Neuromuscular Disorders in Clinical Practice Woburn, MA: Butterworth-Heineman 2002 : 364-383
• 6 Peterson E J, Koretsky G A. Signal transduction in T lymphocytes.  Clin Exp Rheumatol . 1999;  17 107-114
• 7 Halloran P F. Sirolimus and cyclosporin for renal transplantation.  Lancet . 2000;  356 179-180
• 8 Miller D H, Khan O A, Sheremata W A. et al . A controlled trial of Natalizumab for relapsing multiple sclerosis.  N Engl J Med . 2003;  348 15-23
• 9 Lipsky J J. Mycophenolate mofetil.  Lancet . 1996;  348 1357-1359
• 10 Chaudhry V, Cornblath D R, Griffin J W, O'Brien R, Drachman D B. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases.  Neurology . 2001;  56 94-96
• 11 Ciafaloni E, Massey J M, Tucker-Lipscomb B, Sanders D B. Mycophenolate mofetil for myasthenia gravis: an open-label pilot study.  Neurology . 2001;  56 97-99
• 12 Abraham R T. Mammalian target of rapamycin: immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling.  Curr Opin Immunol . 1998;  10 330-336
• 13 Guo X, Dillman III F J, Dawson V L, Dawson T M. Neuroimmunophilins: novel neuroprotective and neuroregenerative targets.  Ann Neurol . 2001;  50 6-16
• 14 Drachman D B, Jones R J, Brodsky R A. Treatment of refractory myasthenia: "rebooting" with high-dose cyclophosphamide.  Ann Neurol . 2003;  53 29-34
• 15 Lewis R A, Lisak R P. "Rebooting" the immune system with cyclophosphamide: taking risks for a "cure"?.  Ann Neurol . 2003;  53 7-9
• 16 Hartung H P, Gonsette R, Konig N. et al . Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial.  Lancet . 2002;  360 2018-2025
• 17 Jacobs L, Johnson K P. A brief history of the use of interferons as treatment of multiple sclerosis.  Arch Neurol . 1994;  51 1245-1251
• 18 Panitch H S, Hirsch R L, Schindler J, Johnson K P. Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system.  Neurology . 1987;  37 1097-1102
• 19 Sibley W A, IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis I: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial.  Neurology . 1993;  43 655-661
• 20 IFNB Multiple Sclerosis Study Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial.  Neurology . 1995;  45 1277-1285
• 21 Jacobs L D, Cookfair D L, Rudick R A. et al . Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis.  Ann Neurol . 1996;  39 285-294
• 22 Ebers G C. PRISM (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis). Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis.  Lancet . 1998;  352 1498-1504
• 23 Kappos L. European Study Group on Interferon-beta in Secondary Progressive MS. Placebo-controlled multicenter randomized trial of interferon β-1b in treatment of secondary progressive multiple sclerosis.  Lancet . 1998;  352 1491-1497
• 24 Stone L A, Frank J A, Albert P S. et al . The effect of interferon-β on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis.  Ann Neurol . 1995;  37 611-619
• 25 Walther E U, Hohlfeld R. Multiple sclerosis: side effects of interferon beta therapy and their management.  Neurology . 1999;  53 1622-1627
• 26 Dayal A S, Jensen M A, Lledo A, Arnason B GW. Interferon-gamma secreting cells in multiple sclerosis patients treated with interferon beta-1b.  Neurology . 1995;  45 2173-2177
• 27 Brod S A, Marshall G D, Henninger E M, Sriram S, Khan M, Wolinsky J S. Interferon-β_1b treatment decreases tumor necrosis factor-α and increases interleukin-6 production in multiple sclerosis.  Neurology . 1996;  46 1633-1638
• 28 IFNB Multiple Sclerosis Study Group, UBC MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years.  Neurology . 1996;  47 889-894
• 29 Khan O A, Dhib-Jalbut S S. Neutralizing antibodies to interferon β-1a and interferon β-1b in MS patients are cross-reactive.  Neurology . 1998;  51 1698-1702
• 30 Yong V W, Chabot S, Stüve O, Williams G. Interferon-β in the treatment of multiple sclerosis: mechanisms of action.  Neurology . 1998;  51 682-689
• 31 Rudick R A, Simonian N A, Alam J A. et al . Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis.  Neurology . 1998;  50 1266-1272
• 32 Bertolotto A, Malucchi S, Sala A. et al . Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory.  J Neurol Neurosurg Psychiatry . 2002;  73 148-153
• 33 Arnon R, Sela M, Teitelbaum D. New insights into the mechanism of action of copolymer 1 in experimental allergic encephalomyelitis and multiple sclerosis.  J Neurol . 1996;  243 (suppl 1) S8-S13
• 34 Neuhaus O, Farina C, Yassouridis A. et al . Multiple sclerosis: comparison of copolymer-I reactive T cell lines from treated and untreated subjects reveals cytokine shift from TH1 to TH2.  Proc Natl Acad Sci U S A . 2000;  97 7452-7457
• 35 Wekerle H, Linington C, Lassmann H, Meyermann R. Cellular immune reactivity within the CNS.  Trends Neurosci . 1986;  9 271-277
• 36 Neuhaus O, Farina C, Wekerle H, Hohlfeld R. Mechanisms of action of glatiramer acetate in multiple sclerosis.  Neurology . 2001;  56 702-706
• 37 Ziemssen T, Kümpfel T, Klinkert W EF, Neuhaus O, Hohlfeld R. Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy.  Brain . 2002;  125 2381-2391
• 38 Dalakas M C. Intravenous immune globulin therapy for neurologic diseases.  Ann Intern Med . 1997;  126 721-730
• 39 Kazatchkine M D, Kaveri S V. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin.  N Engl J Med . 2001;  345 747-755
• 40 Hohlfeld R, Melms A, Schneider C, Toyka K V, Drachman D B. Therapy for myasthenia gravis and myasthenic syndromes. In: Brandt T, Caplan LR, Dichgans J, Diener HC, Kennard C, eds. Neurological Disorders: Course and Treatment 2nd ed. San Diego: Academic Press 2003: 1341-1362
• 41 Yeh J H, Chiu H C. Comparison between double-filtration plasmapheresis and immunoadsorption plasmapheresis in the treatment of patients with myasthenia gravis.  J Neurol . 2000;  247 510-513
• 42 Gronseth G S, Barohn R J. Thymectomy for Myasthenia Gravis.  Curr Treat Options Neurol . 2002;  4 203-209
• 43 Lanska D J. Indications for thymectomy in myasthenia gravis.  Neurology . 1990;  40 1828-1829
• 44 Evoli A, Minisci C, Di Schino C. et al . Thymoma in patients with MG: characteristics and long-term outcome.  Neurology . 2002;  59 1844-1850
• 45 Comi G, Kappos L, Clanet M. et al . Guidelines for autologous blood and marrow stem cell transplantation in multiple sclerosis: a consensus report written on behalf of the European Group for Blood and Marrow Transplantation and the European Charcot Foundation. BMT-MS Study Group.  J Neurol . 2000;  247 376-382
• 46 Hohlfeld R. How promising is hematopoetic stem cell transplantation in multiple sclerosis?.  J Neurol . 2002;  249 1147-1149
• 47 Compston A, Ebers G, Lassmann H, McDonald W I, Matthews B, Wekerle H. McAlpine's Multiple Sclerosis 3rd ed.  London: Churchill Livingstone 1998
• 48 Weilbach F X, Gold R. Disease modifying treatments for multiple sclerosis: what is the horizon?.  CNS Drugs . 1999;  11 133-157
• 49 Hohlfeld R. Biotechnological agents for the immunotherapy of multiple sclerosis: principles, problems and perspectives.  Brain . 1997;  120 865-916
• 50 Martin R, Sturzebecher C S, McFarland H F. Immunotherapy of multiple sclerosis: where are we?.  <~>Where should we go? Nat Immunol . 2001;  2 785-788
• 51 Krummel M F, Davis M M. Dynamics of the immunological synapse: finding, establishing and solidifying a connection.  Curr Opin Immunol . 2002;  14 66-74
• 52 Gold R, Dalakas M C, Toyka K V. Immunotherapy in autoimmune neuromuscular disorders.  Lancet Neurol . 2003;  2 22-32